G/MA/QR/N/CAN/4/Add.2  
 
15 December  2021 
(21-9399) Page: 1/3 
Committee on Market Access  Original: English /French  
 
  
NOTIFICATION PURSUANT TO THE DECISION ON NOTIFICATION  PROCEDURE S 
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)  
CANADA  
Addendum  
The following communication, dated 13 December 202 1, is being circulated at the request of the 
delegation of Canada . 
 
A. Notifying Member :  Canada  
B. Date of notification :  13 December 202 1 
C. First time notification:  
 Yes  
 No, last notification was made in (doc. symbol ): G/MA/QR/N/CAN/ 4/Add.1  
D. Type of notification:  
 1. Complete (i.e. notification of all quantitative restrictions in force ) 
 2. Changes to a notification previously made in (doc symbol)  which are of the following 
nature : 
  2.1 Introduction of new restrictions, as listed in Section 1. 
  2.2 Elimination of restrictions, as described in G below . 
  2.3 Modification of a previously notified restriction, as described in Section 1. 
 3. Reverse notification of restrictions maintained by (Member ):  
E. The notification provides information for the follo wing biennial period 
(e.g.  2012 -2014): 2020-2022 and relates to restrictions in force as of 27.11.2021 
F. This notification contains information* relating to:  
 Section  1: List of quantitative restrictions that are currently in force . 
 Section  2: Cross -reference to other WTO notifications wi th information on quantitative 
restrictions that are currently in force and additional information . 
G. Comments of a general nature, including a description of the elimination of 
restrictions notified under D.2.2 and the date they ceased to be in force.  
Canada is notifying a measure that was adopted to prevent critical shortages of its 
pharmaceutical drug supply.  This measure makes permanent an interim measure that 
was previously notified to the WTO on 17 December 2020.  
 
 
* In English  and French  only.  
  G/MA/QR/N/CAN/4/Add.2  
 
- 2 - Section 1: List of quantitative restrictions that are currently in force  
 
QR 
No. General 
description of 
the restriction  Type of 
restriction  
 Tariff line code(s) 
affected, based on 
HS(2017 ) Detailed 
Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. 
Other International 
Commitments  National legal 
basis and entry 
into force   
 Administration, modification of 
previously notified measures, 
and other comments  
 1 2 3 4 5 6 7 
1 Conditional 
prohibition of 
the export of 
certain 
pharmaceuticals   CP - X Various products under 
HS Chapters 29 and 30  
 
Products include:  
 
1. Drugs included in 
Schedule I, II, III, IV or 
V to the Controlled 
Drugs and Substances 
Act; 
EN  https://laws -
lois.justice.gc.ca/eng/a
cts/c-38.8/   
 
FR  https://laws -
lois.justice.gc.ca/fra/loi
s/c-38.8/   
 
2. Prescription drugs, 
as defined in section 
A.01.010 of the Food 
and Drug Regulations;  
EN  https://laws -
lois.justice.gc.ca/eng/re
gulations/c.r.c.%2C_c.
_870/index.html   
 
FR  https://laws -
lois.justice.gc.ca/fra/re
glements/C.R.C.%2C_c
h._870/index.html   
 
3. Drugs that are listed 
in Schedule C or D to  Pharmaceuticals  Article XI:2(a) of 
the GATT  
Article XX(b) and 
Article XX(g) of the 
GATT  
 Regulations 
Amending Certain 
Regulations 
Concerning Drugs 
and Medical 
Devices 
(Shortages) 
entered into force 
on November 27, 
2021.  
 
Le Règlement 
modifiant certains 
règlements visant 
les drogues et les 
instruments 
médicaux 
(pénuries)  est 
entré en vigueur 
le 27 novembre 
2021.  These Regulations are based on the 
Interim Order Respecting Drug 
Shortages (Safeguarding the Drug 
Supply)  made on N ovember 27, 
2020.  
 
These Regulations do not prohibit 
exports but provides the Minister of 
Health the authority to prohibit  a 
sale of a drug intended for the 
Canadian market for consumption 
outside Canada if it would cause or 
exacerbate a shortage of certain 
categories of drugs.  
 
The distribution of drugs intended 
for the Canadian market for 
consumption outside of Canada 
continues to be permitted in cases 
where the seller determines that the 
sale will not cause or exacerbate a 
shortage.  
 
 
Regulations Amending Certain 
Regulations Concerning Drugs and 
Medical Devices (Shortages)  and 
RIAS:  
https://www.gazette.gc.ca/rp -
pr/p2/2021/2021 -09-01/html/sor -
dors199 -eng.html  
 
  
  
  G/MA/QR/N/CAN/4/Add.2  
 
- 3 - QR 
No. General 
description of 
the restriction  Type of 
restriction  
 Tariff line code(s) 
affected, based on 
HS(2017 ) Detailed 
Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. 
Other International 
Commitments  National legal 
basis and entry 
into force   
 Administration, modification of 
previously notified measures, 
and other comments  
 1 2 3 4 5 6 7 
   the Food and Drugs 
Act; and  
EN  https://laws -
lois.justice.gc.ca/eng/a
cts/f-27/  
 
FR  https://laws -
lois.justice.gc.ca/fra/loi
s/f-27/  
 
4. Drugs that are 
permitted to be sold 
without a prescription, 
as defined in subsection 
C.01.001(1) of the 
Food and Drug 
Regulations, but that 
are to be administered 
only under the 
supervision of a 
practitioner, as defined 
in that subsection.  
EN  https://laws -
lois.justice.gc.ca/eng/re
gulations/c.r.c.%2C_c.
_870/index.html   
 
FR  https://laws -
lois.justice.gc.ca/fra/re
glements/C.R.C.%2C_c
h._870/index.html     Le Règlement modifiant certains 
règlements visant les drogues et les 
instruments médicaux (pénuries)  et 
le REIR : 
https://www.gazette.gc.ca/rp -
pr/p2/2021/2021 -09-01/html/sor -
dors199 -fra.html  
 
 
__________